Vanda Pharmaceuticals Inc (VNDA)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $241.27M
Last updated: Nov 17, 2026 at 11:05 AM ET
Vanda Pharmaceuticals Inc (VNDA) Competitors
The companies most similar to Vanda Pharmaceuticals are Inovio Pharmaceuticals (INO), Invivyd (IVVD) and Nautilus Biotechnology (NAUT). By market cap, Vanda Pharmaceuticals ranks 9th of the 13 companies on this page; Enanta Pharmaceuticals (ENTA) is the largest at $320.09M.
Peer Comparison
VNDA's revenue growth of 24.1% is above the peer median of 0.0%. Like the median peer, it pays no dividend.
| Company | Market cap | P/E | P/S | Net margin | ROIC | Rev growth | Div yield |
|---|---|---|---|---|---|---|---|
| Vanda Pharmaceuticals (VNDA) | $241.27M | N/A | 1.0x | -119.9% | -84.7% | 24.1% | 0.00% |
| Inovio Pharmaceuticals Inc (INO) | $267.85M | N/A | 462.0x | 0.0% | N/A | -100.0% | 0.00% |
| Invivyd Inc. (IVVD) | $171.58M | N/A | 2.9x | -183.9% | N/A | 21.2% | 0.00% |
| Nautilus Biotechnology Inc (NAUT) | $295.50M | N/A | 630.2x | 0.0% | N/A | 0.0% | 0.00% |
| Vivani Medical Inc. (VANI) | $91.11M | N/A | N/A | 0.0% | N/A | 0.0% | 0.00% |
| Prelude Therapeutics Inc (PRLD) | $275.32M | N/A | 16.3x | -269.7% | N/A | 41.0% | 0.00% |
| Rocket Pharmaceuticals Inc (RCKT) | $256.82M | N/A | N/A | 0.0% | -2.3% | 0.0% | 0.00% |
| SAB Biotherapeutics Inc (SABS) | $266.66M | N/A | N/A | 0.0% | N/A | -62.4% | 0.00% |
| Enanta Pharmaceuticals Inc (ENTA) | $320.09M | N/A | 4.8x | -96.9% | N/A | -21.6% | 0.00% |
| Kyverna Therapeutics, Inc. Common Stock (KYTX) | $319.27M | N/A | N/A | 0.0% | -81.5% | 0.0% | 0.00% |
| Oramed Pharmaceuticals Inc (ORMP) | $161.33M | 4.3x | N/A | 0.0% | N/A | -100.0% | 6.41% |
| ProQR Therapeutics BV (PRQR) | $199.28M | N/A | 6.1x | -228.2% | N/A | 120.4% | 0.00% |
| Fulcrum Therapeutics Inc (FULC) | $287.96M | N/A | N/A | 0.0% | N/A | -100.0% | 0.00% |
| Peer median | $267.26M | 4.3x | 11.2x | 0.0% | -41.9% | 0.0% | 0.00% |
Similar Companies
These are the 12 companies most similar to Vanda Pharmaceuticals, ranked by how closely their business, size, sector and industry match. All 12 are in one industry, Biotechnology.
| Company | About | Peers |
|---|---|---|
| Inovio Pharmaceuticals Inc (INO) | Inovio Pharmaceuticals, Inc., a biotechnology company, focuses on the discovery, development... | INO competitors |
| Invivyd Inc. (IVVD) | Adagio Therapeutics, Inc., a clinical-stage biopharmaceutical company, is focused on the discovery... | IVVD competitors |
| Nautilus Biotechnology Inc (NAUT) | Nautilus Biotechnology, Inc., a development-stage life sciences company, is dedicated to creating platform technology to quantify and unlock proteome... | NAUT competitors |
| Vivani Medical Inc. (VANI) | Vivani Medical Inc. (VANI) is a pioneering biotechnology firm focused on revolutionizing chronic disease management through its cutting-edge drug delivery... | VANI competitors |
| Prelude Therapeutics Inc (PRLD) | Prelude Therapeutics Incorporated, a precision clinical-stage oncology company, focuses on the discovery and development of small molecule therapies optimized... | PRLD competitors |
| Rocket Pharmaceuticals Inc (RCKT) | Rocket Pharmaceuticals, Inc., is a cross-platform biotechnology company focused on developing gene therapies for rare and devastating pediatric diseases. | RCKT competitors |
| SAB Biotherapeutics Inc (SABS) | SAB Biotherapeutics, Inc., a biopharmaceutical company, develops immunotherapies against infectious diseases, autoimmune diseases, and oncology. | SABS competitors |
| Enanta Pharmaceuticals Inc (ENTA) | Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. | ENTA competitors |
| Kyverna Therapeutics, Inc. Common Stock (KYTX) | Kyverna Therapeutics, Inc. is an innovative biotechnology company focused on advancing immunotherapies for autoimmune diseases and other significant health... | KYTX competitors |
| Oramed Pharmaceuticals Inc (ORMP) | Oramed Pharmaceuticals Inc. is dedicated to the research and development of pharmaceutical solutions for the treatment of diabetes and for the use of orally... | ORMP competitors |
| ProQR Therapeutics BV (PRQR) | ProQR Therapeutics NV, a biopharmaceutical company, is dedicated to the discovery and development of RNA-based therapies for the treatment of genetic disorders. | PRQR competitors |
| Fulcrum Therapeutics Inc (FULC) | Fulcrum Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing products to improve the lives of patients with genetically defined... | FULC competitors |
Frequently Asked Questions About VNDA
Who are Vanda Pharmaceuticals' main competitors?
The companies most similar to Vanda Pharmaceuticals include Inovio Pharmaceuticals (INO), Invivyd (IVVD), Nautilus Biotechnology (NAUT), Vivani Medical (VANI) and Prelude Therapeutics (PRLD), listed from the closest match.
Who is Vanda Pharmaceuticals' biggest competitor?
Enanta Pharmaceuticals (ENTA) is the largest of the similar companies at $320.09M; Inovio Pharmaceuticals (INO) is the closest match by business profile, size, sector and industry.
How does VNDA stock compare with its competitors?
VNDA's P/S is 1.0x against a peer median of 11.2x; its net margin is -119.9% against a peer median of 0.0%.
Which of Vanda Pharmaceuticals' competitors pays a higher dividend?
Vanda Pharmaceuticals pays no dividend. Oramed Pharmaceuticals (ORMP) has a higher forward dividend yield; Oramed Pharmaceuticals (ORMP) has the highest at 6.41%.
Is Vanda Pharmaceuticals bigger than its competitors?
No. Vanda Pharmaceuticals is 9th by market cap among the 13 companies on this page; the largest is Enanta Pharmaceuticals (ENTA) at $320.09M.
VNDA pages: Overview, Earnings, Forecast, Financials, Valuation, Competitors, Government Contracts